Global Monoclonal Antibodies (MAbS) Market Report 2024

Monoclonal Antibodies (MAs) Global Market Report 2024 – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications), By End Users (Hospitals, Private Clinics, Research Institute) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 250 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Monoclonal Antibodies (MAbS) Market

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Monoclonal Antibodies (Mabs) Market Definition And Segments

Monoclonal antibodies (MABS) refer to laboratory-produced proteins intended to boost your immune system. Treatments for monoclonal antibodies are often administered as IV solutions, frequently in an infusion center. Antibodies are a component of your immune system. To kill them, they seek out the antigens (foreign substances) and adhere to them.

The main types of sources of monoclonal antibodies (MABS) are murine, chimeric, humanized, and human. A murine antibody has two types of chains, one of which is from a mouse and the other from a human. The pre-stem -o- in the INN of a murine antibody is used to identify it. It is used in anti-cancer, immunological, anti-infective monoclonal antibodies (MAbs), neuropharmacological, cardiovascular, cerebrovascular, and other applications and is implemented in various sectors such as hospitals, private clinics, and research institutes.

The monoclonal antibodies (MAbs) market covered in this report is segmented –

1) By Source: Murine, Chimeric, Humanized, Human

2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications

3) By End Users: Hospitals, Private Clinics, Research Institute

The monoclonal antibodies (mabs) market size has grown rapidly in recent years. It will grow from $234.37 billion in 2023 to $261.66 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to prevalence of chronic diseases, increasing investment in R&D, growing awareness of mabs, growing elderly population.

The monoclonal antibodies (mabs) market size is expected to see rapidly grown in the next few years. It will grow to $424.24 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to expanding therapeutic indications, personalized medicine, biosimilars and generics, combination therapies, pandemic preparedness, biopharmaceutical investment. Major trends in the forecast period include immunotherapy advancements, subcutaneous administration, next-generation antibodies, subcutaneous formulations, digital health integration, advancements in biotechnology.

Rising Popularity Of Cost-Efficient Biosimilar Monoclonal Antibodies Fuels Monoclonal Antibody Market Growth

The increasing prevalence of cost-efficient biosimilar monoclonal antibodies is driving the monoclonal antibody market's growth. The biosimilars' aim is to curb the increasing cost of healthcare and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilars are pharmaceuticals that are developed to have similar properties to a biological drug that has already been approved. A biosimilar monoclonal antibody costs 20%–25% less than the original biologic drug. The number of clinical trials for a biosimilar is comparatively smaller than that of the original biologic drug, and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry.

Chronic Disease Prevalence Driving Growth In The Monoclonal Antibodies (MABS) Market

The increasing prevalence of chronic diseases is expected to propel the growth of the monoclonal antibodies (mAbs) market going forward. Chronic diseases are long-lasting conditions that usually cannot be cured but can be managed with proper medical attention and lifestyle changes. Monoclonal antibodies (mAbs) have been employed in the treatment of various chronic diseases, particularly those characterized by dysregulated immune responses, excessive inflammation, and specific molecular targets. For instance, in September 2023, according to the World Health Organization, noncommunicable diseases (NCDs) or chronic diseases kill 41 million people each year, equivalent to 74% of all deaths globally. Annually, 17 million individuals experience premature deaths due to non-communicable diseases (NCDs) also known as chronic diseases, before reaching the age of 70. A significant majority, specifically 86% of these early fatalities, take place in low- and middle-income countries. Therefore, the ongoing rise in the incidence of chronic diseases will persist in propelling the expansion of the monoclonal antibodies (mAbs) market.

Major companies operating in the monoclonal antibodies (MABS) market include Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Amgen Inc., Novartis International AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Mylan N.V., Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics Inc., Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Inc., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Biopharma Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd., Piramal Enterprises Ltd., Troikaa Pharmaceuticals Ltd., CD BioSciences Inc., Kanto Corporation, Molecular Depot LLC, Epigentek Group Inc., Creative Biolabs Inc., Advanced ChemTech Inc., Diagnostic BioSystems Inc., Tonbo Biosciences Inc., Abraxis LLC, GlaxoSmithKline plc

Growth Of Alternative And Natural Therapies Challenges Monoclonal Antibody Drug Market

Alternative treatment methods and natural remedies are increasingly popular globally, and this is expected to hurt the revenues of the monoclonal antibody drugs market. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, the revenue from US retail sales of homeopathic and herbal remedies was around $7.5 billion. These less expensive alternatives increase the competitiveness of the biologics market, putting downward pressure on prices and limiting the demand for monoclonal antibody drugs.

Strategic Expansion And Collaborative Initiatives Shaping The Monoclonal Antibody Market

The monoclonal antibody market has been witnessing multiple strategic initiatives in recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden their products and services. Strategic collaborations, acquisitions, and partnership agreements help vendors expand their existing product portfolio and geographical reach. For instance, in March 2022, Sanofi S.A., a France-based pharmaceutical and healthcare company specializing in the discovery, development, manufacturing, and commercialization of drugs, announced a strategic collaboration with Seagen Inc., a US-based pharmaceutical company specializing in the development and commercialization of novel, powerful monoclonal antibody-based cancer treatments. Under this agreement, the partnership will use Seagen's and Sanofi's exclusive monoclonal antibody (mAb) and antibody-drug conjugate (ADC) technologies to design, develop, and market ADCs for up to three cancer targets. Furthermore, Boehringer Ingelheim, a Germany-based research-driven pharmaceutical company, announced a collaboration with MabGenesis, Inc., a Japan-based biopharmaceutical company pioneering the development of therapeutic monoclonal antibody drugs for the treatment of human diseases. Through this collaboration, Boehringer Ingelheim and MabGenesis discovered and developed novel therapeutic monoclonal antibodies for the treatment of various diseases and strategic research and development strategies. Companies in the industry are increasingly realigning their portfolios and pursuing profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favorable interest rates globally.

Innovative Technologies To Enhance Competitiveness In The Monoclonal Antibodies Market

Major companies operating in the monoclonal antibodies market are introducing innovative technologies such as RenMice to gain a competitive edge in the market. RenMice offers strong assistance in the exploration of various antibody-based therapies, including fully human monoclonal antibodies, bispecific antibodies, bispecific antibody-drug conjugates (BsADCs), nanobodies, fully human T-cell receptors (TCRs), and TCR-mimic antibodies. For instance, in September 2023, Biocytogen Pharmaceuticals, a China-based international biotech company that drives the research and development of new drugs with innovative technologies launched the RenMice series, encompassing a selection of independently created fully human antibody mice and TCR mice, all of which possess proprietary intellectual property.

FDA's Regulatory Support And Accelerated Approvals Bolstering The Monoclonal Antibody Therapeutics Market

The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services, in the USA, regulating the monoclonal antibody and pharmaceutical drug markets. Increasing product launches and regulatory support for the treatment of rare diseases by the USFDA are expected to support the monoclonal antibody therapeutics market's growth. For instance, the U.S. The Food and Drug Administration (FDA) granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.), a human monoclonal antibody, for the treatment of a rare disease, metastatic Merkel cell carcinoma (MCC). Similarly, the U.S. FDA granted accelerated approval to the immunotherapy product TECENTRIQ (atezolizumab), a humanized, engineered monoclonal antibody, for the treatment of people with locally advanced or metastatic urothelial carcinoma (MUC).

North America was the largest region in the monoclonal antibodies (MAbS) market in 2023. The regions covered in the monoclonal antibodies (MABS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the monoclonal antibodies (MABS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The monoclonal antibodies (MABS) market consists of sales of rituximab, cetuximab, and trastuzumab. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The monoclonal antibodies (MABS) market research report is one of a series of new reports from The Business Research Company that provides monoclonal antibodies (MABS) market statistics, such as industry global market size, regional shares, competitors with a monoclonal antibodies (MABS) market share, detailed monoclonal antibodies (MABS) market segments, market trends and opportunities, and any additional data you may require to thrive in the monoclonal antibodies (MABS) industry. This monoclonal antibody (MABS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Monoclonal Antibodies (MAs) Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $261.66 billion
Revenue Forecast In 2033 $424.24 billion
Growth Rate CAGR of 12.8% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Source: Murine, Chimeric, Humanized, Human
2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications
3) By End Users: Hospitals, Private Clinics, Research Institute
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Amgen Inc.; Novartis International AG; Pfizer Inc.; Thermo Fisher Scientific Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Sanofi S.A.; Abbott Laboratories; Mylan N.V.; Novo Nordisk A/S; Daiichi Sankyo Company Ltd.; Seattle Genetics Inc.; Teva Pharmaceutical Industries Ltd.; Shanghai Junshi Biosciences Co. Ltd.; GenScript Biotech Corporation; Sigma-Aldrich Co. LLC; AbGenomics Inc.; ADC Therapeutics SA; Agensys Inc.; Alexion Pharmaceuticals Inc.; ALMAC Group Ltd.; Ambrx Biopharma Inc.; Astellas Pharma Inc.; Celgene Corporation; Celldex Therapeutics Inc.; Baxter International Inc.; Fresenius SE & Co. KGaA; Hikma Pharmaceuticals plc; Jiangsu Hengrui Medicine Co. Ltd.; Piramal Enterprises Ltd.; Troikaa Pharmaceuticals Ltd.; CD BioSciences Inc.; Kanto Corporation; Molecular Depot LLC; Epigentek Group Inc.; Creative Biolabs Inc.; Advanced ChemTech Inc.; Diagnostic BioSystems Inc.; Tonbo Biosciences Inc.; Abraxis LLC; GlaxoSmithKline plc
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Monoclonal Antibodies (MAs) Market Characteristics

    3. Monoclonal Antibodies (MAs) Market Trends And Strategies

    4. Monoclonal Antibodies (MAs) Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Monoclonal Antibodies (MAs) Market Size and Growth

    5.1. Global Monoclonal Antibodies (MAs) Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Monoclonal Antibodies (MAs) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Monoclonal Antibodies (MAs) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Monoclonal Antibodies (MAs) Market Segmentation

    6.1. Global Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Murine

    Chimeric

    Humanized

    Human

    6.2. Global Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Anti-Cancer

    Immunological

    Anti-Infective Monoclonal Antibodies (MAs)

    Neuropharmacological

    Cardiovascular And Cerebrovascular

    Other Applications

    6.3. Global Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Private Clinics

    Research Institute

    7. Monoclonal Antibodies (MAs) Market Regional And Country Analysis

    7.1. Global Monoclonal Antibodies (MAs) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Monoclonal Antibodies (MAs) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Monoclonal Antibodies (MAs) Market

    8.1. Asia-Pacific Monoclonal Antibodies (MAs) Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Monoclonal Antibodies (MAs) Market

    9.1. China Monoclonal Antibodies (MAs) Market Overview

    9.2. China Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Monoclonal Antibodies (MAs) Market

    10.1. India Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Monoclonal Antibodies (MAs) Market

    11.1. Japan Monoclonal Antibodies (MAs) Market Overview

    11.2. Japan Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Monoclonal Antibodies (MAs) Market

    12.1. Australia Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Monoclonal Antibodies (MAs) Market

    13.1. Indonesia Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Monoclonal Antibodies (MAs) Market

    14.1. South Korea Monoclonal Antibodies (MAs) Market Overview

    14.2. South Korea Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Monoclonal Antibodies (MAs) Market

    15.1. Western Europe Monoclonal Antibodies (MAs) Market Overview

    15.2. Western Europe Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Monoclonal Antibodies (MAs) Market

    16.1. UK Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Monoclonal Antibodies (MAs) Market

    17.1. Germany Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Monoclonal Antibodies (MAs) Market

    18.5. France Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Monoclonal Antibodies (MAs) Market

    19.9. Italy Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Monoclonal Antibodies (MAs) Market

    20.13. Spain Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Monoclonal Antibodies (MAs) Market

    21.1. Eastern Europe Monoclonal Antibodies (MAs) Market Overview

    21.2. Eastern Europe Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Monoclonal Antibodies (MAs) Market

    22.1. Russia Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Monoclonal Antibodies (MAs) Market

    23.1. North America Monoclonal Antibodies (MAs) Market Overview

    23.2. North America Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Monoclonal Antibodies (MAs) Market

    24.1. USA Monoclonal Antibodies (MAs) Market Overview

    24.2. USA Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Monoclonal Antibodies (MAs) Market

    25.1. Canada Monoclonal Antibodies (MAs) Market Overview

    25.2. Canada Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Monoclonal Antibodies (MAs) Market

    26.1. South America Monoclonal Antibodies (MAs) Market Overview

    26.2. South America Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Monoclonal Antibodies (MAs) Market

    27.1. Brazil Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Monoclonal Antibodies (MAs) Market

    28.1. Middle East Monoclonal Antibodies (MAs) Market Overview

    28.2. Middle East Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Monoclonal Antibodies (MAs) Market

    29.1. Africa Monoclonal Antibodies (MAs) Market Overview

    29.2. Africa Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Monoclonal Antibodies (MAs) Market Competitive Landscape And Company Profiles

    30.1. Monoclonal Antibodies (MAs) Market Competitive Landscape

    30.2. Monoclonal Antibodies (MAs) Market Company Profiles

    30.2.1. Johnson & Johnson

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Merck & Co. Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. AbbVie Inc.

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Amgen Inc.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Novartis International AG

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Monoclonal Antibodies (MAs) Market Competitive Benchmarking

    32. Global Monoclonal Antibodies (MAs) Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Monoclonal Antibodies (MAs) Market

    34. Monoclonal Antibodies (MAs) Market Future Outlook and Potential Analysis

    34.1 Monoclonal Antibodies (MAs) Market In 2028 - Countries Offering Most New Opportunities

    34.2 Monoclonal Antibodies (MAs) Market In 2028 - Segments Offering Most New Opportunities

    34.3 Monoclonal Antibodies (MAs) Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Monoclonal Antibodies (MAs) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Monoclonal Antibodies (MAs) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Johnson & Johnson Financial Performance
  • Table 75: Merck & Co. Inc. Financial Performance
  • Table 76: AbbVie Inc. Financial Performance
  • Table 77: Amgen Inc. Financial Performance
  • Table 78: Novartis International AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Monoclonal Antibodies (MAs) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Monoclonal Antibodies (MAs) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Monoclonal Antibodies (MAs) Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Monoclonal Antibodies (MAs) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Monoclonal Antibodies (MAs) Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Johnson & Johnson Financial Performance
  • Figure 75: Merck & Co. Inc. Financial Performance
  • Figure 76: AbbVie Inc. Financial Performance
  • Figure 77: Amgen Inc. Financial Performance
  • Figure 78: Novartis International AG Financial Performance
Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
Read More
Global Gene Therapy Market 2022 – Market Opportunities And Strategies
Read More
The Microbiome Market Share, Market Size, And Growth Rate 2022
Read More
Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
Read More
Drugs for Immunotherapy Global Market Report 2024 – By Type (Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types), By Therapy Area (Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Antibody Drug Conjugates Global Market Report 2024 – By Type (Monoclonal Antibodies, Linker, Drug/Toxin, Other Types), By Product (Adcertis, Kadcyla, Other Products), By Technology (Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology), By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications), By End User (Hospital, Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Biosimilars Global Market Report 2024 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others), By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Biosimilar Monoclonal Antibodies Global Market Report 2024 – By Type (Synthetic Chemicals, Biopharmaceuticals, Other Types), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab), By Application (Chronic & Autoimmune Diseases, Oncology, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Research Antibodies and Reagents Global Market Report 2024 – By Technology (Western Blot, Immunofluorescence, Immunohistochemistry, Flow Cytometry, Enzyme-Linked Immunosorbent Assay (Elisa), Others), By Application (Proteomics, Genomics, Other Applications), By End User (Pharmaceutical & Biotechnology Industry, Academic & Research Institutes, Contract Research Organizations (CROs)) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Conjugated Monoclonal Antibodies Global Market Report 2024 – By Drugs (Adcetris, Kadcyla), By Technology (Cleavable Linker, Non-cleavable Linker), By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Pharmaceutical Drugs And Biologics Logistics Market 2021 - By Type Of Service (Cold Chain Logistics, Non-Cold Chain Logistics), By Mode Of Transport (Air Transportation, Ocean Transportation, Land Transportation), By Pharmaceutical Type (Pharmaceutical Drugs, Biologics), By Therapeutic Area (Metabolic Disorders Drugs, Anti-Infective Drugs, Central Nervous System Drugs, Respiratory Diseases Drugs, Cardiovascular Drugs, Musculoskeletal Disorders Drugs, Oncology Drugs, Hematology Drugs, Monoclonal Antibodies (MAbS), Genito-Urinary Drugs, Gastrointestinal Drugs, Therapeutic Proteins, Dermatology Drugs, Vaccines, Ophthalmology Drugs), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
Anti-Asthmatic And COPD Drugs Market 2021 - By Drug Class (Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs), By End User (Asthma Patients, COPD Patients), By Distribution Channel (General Pharmacies, Hospital Pharmacies, Online Retailers), By Therapy (Preventive, Curative), By Route Of Administration (Oral, Inhaled, Intravenous, Subcutaneous), By Age Group (Below 5, 5-14, 15-60, Above 60), By Prescription (Prescription, Over The Counter (OTC)), By Drug Type (Branded, Generic) And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report

Frequently Asked Questions

What is the definition of the monoclonal antibodies (MAbs) market?

Monoclonal antibodies (MAbs) refer to laboratory-produced proteins intended to boost your immune system. Treatments for monoclonal antibodies are often administered as IV solutions, frequently in an infusion center. Antibodies are a component of your immune system.To kill them, they seek out the antigens (foreign substances) and adhere to them. For further insights on the monoclonal antibodies (MAbs) market, request a sample here

How will the monoclonal antibodies (MAbs) market drivers and restraints affect the monoclonal antibodies (MAbs) market dynamics? What forces will shape the monoclonal antibodies (MAbs) industry going forward?

The monoclonal antibodies (MAbs) market growth is aided by increasing prevalence of cost-efficient biosimilar monoclonal antibodies. However, some monoclonal antibodies (MAbs) market restraints include increasing popularity of alternative treatment methods and natural remedies. For further insights on the monoclonal antibodies (MAbs) market, request a sample here

What is the forecast market size or the forecast market value of the monoclonal antibodies (MAbs) market?

The monoclonal antibodies (MAbs) market is expected to reach $330.35 billion in 2027 at a rate of 12.0%. For further insights on the monoclonal antibodies (MAbs) market, request a sample here

How is the monoclonal antibodies (MAbs) market segmented?

The global monoclonal antibodies (MAbs) market is segmented as
1) By Source: Murine, Chimeric, Humanized, Human
2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications
3) By End Users: Hospitals, Private Clinics, Research Institute
For further insights on the monoclonal antibodies (MAbs) market, request a sample here

Which region has the largest share of the monoclonal antibodies (MAbs) market? What are the largest region's market size and growth rate?

North America was the largest region in the monoclonal antibodies (MAbs) market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Who are the major players in the monoclonal antibodies (MAbs) market?

Key competitors in the monoclonal antibodies (MAbs) market are, Johnson & Johnson, Merck, AbbVie, Amgen, Glaxosmithkline plc, Norvatis AG, Pfizer Inc, Thermofischer Scientific, Elililly and Company, Bristol-Myers Squibb, Hoffman Roche Ltd, Sanofi, Abbott Laboratories, Mylan N.V, Novo Nordisk A/S, Daiichi Sankyo Company ltd., Seattle genetics, Teva pharmaceutical industries, Shanghi Junsi bioscience ltd, GenScript, Sigma-Aldrich Co. LLC, AbGenomics, ADC Therapeutics, Agensys, Alexion Pharmaceuticals, ALMAC Group, Ambrx, Astellas Pharma, Celgene, Celldex Therapeutics. For further insights on the monoclonal antibodies (MAbs) market, request a sample here.

What are the key trends in the monoclonal antibodies (MAbs) market?

Major trends influencing the monoclonal antibodies (MAbs) market include witnessing multiple strategic initiatives in recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden their products and services. Strategic collaborations, acquisitions, and partnership agreements help vendors expand their existing product portfolio and geographical reach. For further insights on the monoclonal antibodies (MAbs) market, request a sample here.

What are the major opportunities in the monoclonal antibodies (MAbs) market? What are the strategies for the monoclonal antibodies (MAbs) market?

For detailed insights on the major opportunities and strategies in the monoclonal antibodies (MAbs) market, request a sample here.

How does the monoclonal antibodies (MAbs) market relate to the overall economy and other similar markets?

For detailed insights on monoclonal antibodies (MAbs) market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the monoclonal antibodies (MAbs) industry?

For detailed insights on the mergers and acquisitions in the monoclonal antibodies (MAbs) industry, request a sample here.

What are the key dynamics influencing the monoclonal antibodies (MAbs) market growth? SWOT analysis of the monoclonal antibodies (MAbs) market.

For detailed insights on the key dynamics influencing the monoclonal antibodies (MAbs) market growth and SWOT analysis of the monoclonal antibodies (MAbs) industry, request a sample here.